What does US$8 billion (A$12.25 billion) buy you? Former graphic arts giant Fujifilm has provided pictures of its Hillerød site in Denmark, about bring new biologics capacity into production.

The development results from Fujifilm Corporation’s US$8 billion investment in a global network for biologics manufacturing since 2011.

Its Fujifilm Diosynth Biotechnologies is a contract development and manufacturing organisation for biologics, vaccines, advanced therapies and oncolytic viruses.

The first phase (pictured) adds six mammalian cell bioreactors, bringing total capacity at Hillerød site to 12 x 20,000 L bioreactors. A previously announced major capital investment will support the next phase, which will include an additional eight 20,000 L bioreactors and two downstream processing streams. Fill/finish production starts next year and will create up to 2,200 more jobs.  

Senior vice president and site head Christian Houborg says the expansion is testament to a vision for introducing robust capabilities into the global biopharma landscape.

Next year will also see operations start at Fujifilm Diosynth Biotechnologies’ large-scale facility in Holly Springs, North Carolina. The global network will also include further developments in the US, UK and Japan.

Seems a long time since Fujifilm was just the graphic arts brand its name suggests.